- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Bone conduction.
Displaying page 1 of 1.
EudraCT Number: 2013-005588-24 | Sponsor Protocol Number: AM-101-CL-12-03 | Start Date*: 2014-05-27 | |||||||||||
Sponsor Name:Auris Medical Inc. | |||||||||||||
Full Title: AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) – an open-label extension to the TACTT2 study | |||||||||||||
Medical condition: Treatment of peripheral tinnitus following traumatic cochlear injury or otitis media | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001527-39 | Sponsor Protocol Number: AM-101-CL-12-04 | Start Date*: 2013-11-21 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – an open-label extension to the TACTT3 study | |||||||||||||
Medical condition: Treatment of peripheral tinnitus following traumatic cochlear injury or otitis media | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) DE (Completed) AT (Completed) GB (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005166-58 | Sponsor Protocol Number: AM-111-CL-15-01 | Start Date*: 2017-10-12 | |||||||||||
Sponsor Name:Auris Medical Inc. | |||||||||||||
Full Title: Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT) | |||||||||||||
Medical condition: Idiopathic sudden sensorineural hearing loss. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002077-21 | Sponsor Protocol Number: AM-111-CL-13-01 | Start Date*: 2015-10-15 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss | |||||||||||||
Medical condition: Idiopathic sudden sensorineural hearing loss | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) HU (Completed) ES (Prematurely Ended) DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004921-33 | Sponsor Protocol Number: R475-OA-1758 | Start Date*: 2018-11-09 | ||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients with Pain Due to Osteoarthritis of the Hip or Knee | ||||||||||||||||||
Medical condition: Pain due to osteoarthritis of the hip or knee | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004060-40 | Sponsor Protocol Number: AGO15 | Start Date*: 2008-03-13 |
Sponsor Name:Studienzentrale AGO Austria | ||
Full Title: Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer | ||
Medical condition: primary advanced or recurrent/metastatic endometrial cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001958-10 | Sponsor Protocol Number: MD2018 | Start Date*: 2018-10-25 |
Sponsor Name:Abteilung für Hals-, Nasen- und Ohrenkrankheiten MUW, AKH Wien | ||
Full Title: Dexamethasone 21-dihydrogenphosphat and Triamcinolone acetonide in the treatment of Menière´s disease: a randomized, multicentric efficacy trial | ||
Medical condition: In our study we try to evaluate the effect of intratympanic Triamcinolon acetonide and Dexamethason 21-dihydrohenphosphat on vertigo control calculation, Hydrops MRI, vHIT (video head impuls test),... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2019-001540-22 | Sponsor Protocol Number: MD2019 | Start Date*: 2020-01-22 |
Sponsor Name:Abteilung für Hals- Nasen- Ohrenkrankheiten MUW, AKH Wien | ||
Full Title: Assessment of vertigo control rate following common treatments in Menière´s disease | ||
Medical condition: In our study we try to evaluate the the effect of common therapies in Menière´s disease patients on vertigo control calculation, Hydrops MRI, vHIT (video head impuls test) , caloric testing, audiol... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-002672-25 | Sponsor Protocol Number: STR001-201 | Start Date*: 2015-11-18 |
Sponsor Name:Strekin AG | ||
Full Title: A Phase II multicenter, placebo-controlled, proof-of-concept study evaluating the safety, and efficacy of intratympanic STR001 thermogel to preserve residual hearing in adults undergoing cochlear ... | ||
Medical condition: Prevention of Hearing Loss after Cochlear Implant Surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000300-42 | Sponsor Protocol Number: 03AR0298 | Start Date*: 2013-01-18 |
Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | ||
Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome) | ||
Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-004099-20 | Sponsor Protocol Number: AM-101-CL-12-02 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3 (TACTT3) | |||||||||||||
Medical condition: acute peripheral tinnitus following traumatic cochlear injury or otitis media | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) DE (Completed) AT (Completed) GB (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005182-35 | Sponsor Protocol Number: BO20906 | Start Date*: 2008-06-20 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chem... | |||||||||||||
Medical condition: Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IE (Prematurely Ended) LV (Prematurely Ended) ES (Completed) BE (Prematurely Ended) AT (Completed) SK (Completed) CZ (Completed) HU (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004868-30 | Sponsor Protocol Number: PNET5MB | Start Date*: 2013-10-31 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (... | |||||||||||||
Medical condition: Children with medulloblastoma. Medulloblastoma is a highly cellular malignant embryonal neoplasm. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) NO (Completed) CZ (Trial now transitioned) NL (Trial now transitioned) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002673-35 | Sponsor Protocol Number: Fos.06/2016 | Start Date*: 2017-03-29 |
Sponsor Name:PRO-IMPLANT Foundation | ||
Full Title: Efficacy and safety of intravenous fosfomycin in prosthetic joint infection (PJI) caused by staphylococci, streptococci, enterococci and gram-negative bacilli, including mixed infections and cultur... | ||
Medical condition: Prosthetic joint infection of knee, hip or shoulder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003812-98 | Sponsor Protocol Number: BUTTERFLY | Start Date*: 2023-04-04 | |||||||||||
Sponsor Name:Institute of Mother and Child | |||||||||||||
Full Title: To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma. | |||||||||||||
Medical condition: Ewing's sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000763-33 | Sponsor Protocol Number: 20160283 | Start Date*: 2017-12-01 |
Sponsor Name:Amgen, Inc. | ||
Full Title: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Efavaleukin Alfa in Adult Subjects with Steroid Refractory Chronic Graft versu... | ||
Medical condition: Steroid Refractory Chronic Graft versus Host Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003434-18 | Sponsor Protocol Number: IBCSG 32-05/ BIG 1-05 | Start Date*: 2006-05-04 |
Sponsor Name:International Breast Cancer Study Group (IBCSG) | ||
Full Title: Phase III Trials Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suit... | ||
Medical condition: Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrin... | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: SE (Prematurely Ended) HU (Completed) SI (Completed) IT (Completed) BE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000128-16 | Sponsor Protocol Number: 2011-003 | Start Date*: 2012-07-30 | |||||||||||
Sponsor Name:Onyx Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002834-59 | Sponsor Protocol Number: SNFCT2015-05 | Start Date*: 2016-11-28 | |||||||||||||||||||||
Sponsor Name:Sanifit Therapeutics S.A. | |||||||||||||||||||||||
Full Title: A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patie... | |||||||||||||||||||||||
Medical condition: Cardiovascular calcification in blood vessels in end-stage-renal-disease (ESRD) patients on haemodialysis (HD). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
